Alemtuzumab for multiple sclerosis New
Alemtuzumab for multiple sclerosis New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this entry is available only to subscribers.
Citation
"Alemtuzumab for Multiple Sclerosis New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/437939/all/Alemtuzumab_for_multiple_sclerosis:_Cochrane_systematic_review. Accessed 20 May 2022.
Alemtuzumab for multiple sclerosis New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/437939/all/Alemtuzumab_for_multiple_sclerosis:_Cochrane_systematic_review. Accessed May 20, 2022.
Alemtuzumab for multiple sclerosis New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/437939/all/Alemtuzumab_for_multiple_sclerosis:_Cochrane_systematic_review
Alemtuzumab for Multiple Sclerosis New [Internet]. In: Cochrane Abstracts. [cited 2022 May 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/437939/all/Alemtuzumab_for_multiple_sclerosis:_Cochrane_systematic_review.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Alemtuzumab for multiple sclerosis New
ID - 437939
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/437939/all/Alemtuzumab_for_multiple_sclerosis:_Cochrane_systematic_review
DB - Evidence Central
DP - Unbound Medicine
ER -